Trial Profile
A phase II study to evaluate INP-104 for migraine.
Status:
Recruiting
Phase of Trial:
Phase II
Latest Information Update: 22 Sep 2022
Price :
$35
*
At a glance
- Drugs Dihydroergotamine mesilate (Primary)
- Indications Migraine
- Focus Therapeutic Use
- 25 Jan 2017 New trial record